CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced that it will present multiple new analyses on its MASH therapy, Rezdiffra (resmetirom), at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place November 7–11 in Washington, D.C.
The company plans to showcase fresh findings from the open-label arm of its Phase 3 MAESTRO-NAFLD-1 trial, which evaluated Rezdiffra in patients with compensated MASH cirrhosis — a difficult-to-treat population with no approved therapies. Additional presentations will feature new real-world data on treatment outcomes and biomarker responses.
“The pace of scientific innovation in MASH continues to accelerate, but there remains an urgent need for an approved therapy to treat patients with compensated cirrhosis,” said Dr. David Soergel, Chief Medical Officer of Madrigal. “At this year’s Liver Meeting, Madrigal will present important new data that reinforce our confidence in Rezdiffra’s potential to benefit even the most advanced patients.”
Rezdiffra, a once-daily oral thyroid hormone receptor (THR)-β agonist, is the first FDA-approved therapy for noncirrhotic MASH with moderate to advanced fibrosis. The treatment has demonstrated significant improvements in fibrosis, liver stiffness, and lipid profiles in the pivotal MAESTRO-NASH Phase 3 trial.
Madrigal’s upcoming AASLD presentations include two oral sessions and several posters highlighting biomarker correlations, imaging advances, and real-world effectiveness. Researchers will also present data on disease burden, quality-of-life improvements, and treatment patterns among MASH and MASLD patients.
The company continues to study Rezdiffra in advanced stages of liver disease through its ongoing Phase 3 MAESTRO-NASH-OUTCOMES trial, aiming to expand treatment options for patients with compensated cirrhosis — a group facing some of the highest risks of liver-related mortality.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.